1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Leo Sets Up For A David & Goliath Showdown In Atopic Dermatitis

 
• By Jessica Merrill

Scrip talked to Leo Pharma's new CEO Catherine Mazzacco about going up against big biopharma players in dermatology and plans to file tralokinumab in 2020.

Small dog versus bigger dog
Leo will compete against big pharma players in atopic dermatitis • Source: Shutterstock

Danish dermatology specialist Leo Pharma AS thinks it can leverage tralokinumab to become a global leader in atopic dermatitis, a big ambition given the competition in the space. The interleukin-13 blocker is a pillar of the company's expansion outside of topical psoriasis treatments, where it has a strong position.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.